Phase II study of ironotecan plus capecitabine in patients with antracycline and taxane pretreated metastatic breast cancer.

Trial Profile

Phase II study of ironotecan plus capecitabine in patients with antracycline and taxane pretreated metastatic breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2011

At a glance

  • Drugs Capecitabine; Irinotecan
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Dec 2011 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 29 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top